Future Weight-Loss Treatments: What's Coming and What's Here Now
Two recent oral options in this pipeline, Wegovy tablets and orforglipron/Foundayo, are FDA-approved. Retatrutide, CagriSema, and other candidates remain investigational and are not for sale. This page separates current FDA approval from investigational status and links to primary records.
The pipeline at a glance
New treatments are advancing fast and the headlines blur what is real. Here is what is out there, with links to our honest guide on each:
- Retatrutide: investigational triple-hormone injection, not FDA-approved or for sale.
- CagriSema: investigational and not FDA-approved or for sale.
- Orforglipron (Foundayo): FDA-approved April 2026; the first daily small-molecule GLP-1 pill.
- Oral Wegovy (the pill): FDA-approved December 2025; the semaglutide tablet.
- The full 2026 to 2028 pipeline: our honest patient map of every drug, approved and investigational.
How to read the status labels
FDA approval applies to a specific finished product, formulation, indication, and population. It does not automatically extend to a different formulation or a compounded preparation. Investigational means the candidate has not received FDA approval for sale.
- Retatrutide and cagrilintide are investigational. FDA states they cannot be used in compounding under federal law.
- Do not buy a product labeled "research use only" for personal use.
- When a status changes, verify the approval letter and current prescribing information rather than relying on a headline.
Questions to ask when a treatment reaches the market
- Which exact product, dose, route, indication, and population did FDA approve?
- What benefits and adverse effects were observed in the supporting trials?
- Which contraindications, warnings, interactions, and monitoring instructions appear in the current label?
- Is the product actually available for this patient and location?
Primary status sources
- FDA Foundayo approval announcement, April 1, 2026
- FDA-approved Foundayo prescribing information
- FDA Wegovy tablet approval letter, December 22, 2025
- FDA concerns with unapproved GLP-1 drugs, including retatrutide and cagrilintide
- Drugs@FDA approval database
Status checked August 12, 2026. This noindex page includes a free informational updates list but does not sell or reserve investigational drugs. Drug status can change; verify the current FDA record. This is not medical advice.
Be the first to know when what's next arrives
New weight-loss treatments are advancing fast. Join our free updates list and we will let you know the moment new options become available and appropriate, with no obligation.
This is a free updates list, not a purchase or a medication reservation. Investigational treatments like retatrutide are not FDA-approved and are not available for sale. We will only contact you about treatments that are actually available.
What you can start today
In the meantime, here is what a licensed clinic can actually offer now: after a one-time $119 medical review with Dr. Sharma, eligible patients may begin a physician-supervised program. Published compounded semaglutide pricing is $499 for 90 days, approximately $166 per month within the package, and compounded tirzepatide starts at $699 for 90 days, approximately $233 per month at the starting price. Those equivalents are not separate monthly purchases. A $199 one-month Skeptics' Trial is also published. Compounded semaglutide and tirzepatide are not FDA-approved or brand-identical and have not undergone FDA premarket review for safety, effectiveness, or quality. Results vary. Any prescription depends on individualized medical review and lawful pharmacy fulfillment for the patient's location.
Book my $119 review Read the food-noise guide
Common questions
Is retatrutide available at New Hope Weight Loss?
No. Retatrutide is investigational and has not been approved by the FDA. It is not available for sale anywhere, only through the manufacturer's clinical trials. We do offer physician-supervised compounded options today; ask us what is appropriate for you.
Can I join a waitlist for future treatments?
Yes. You can join our updates list to be notified when new treatments become available and appropriate. Joining is free and is not a purchase or a reservation of any medication.
What can I start with right now?
After a one-time $119 medical review with Dr. Sharma, compounded semaglutide is published at $499 for 90 days and compounded tirzepatide from $699 for 90 days. A prescription is a separate clinical decision, eligibility and availability vary, and compounded medications are not FDA-approved or brand-identical.
This page is educational and is not medical advice. Investigational medications are not FDA-approved, not for sale, and not offered at New Hope Weight Loss. Individual results vary and are not guaranteed.